Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler & Manja Kamprad. (2009) Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. Biologics: Targets and Therapy 3, pages 27-37.
Read now
Read now
Articles from other publishers (15)
Yuki Endo, Takeshi Ishikawa, Kaname Oka, Tomoki Sakakida, Shinya Matsumura, Katsura Mizushima, Toshifumi Doi, Tetsuya Okayama, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama, Tomohisa Takagi, Hitoshi Fujiwara, Hideyuki Konishi, Yuji Naito & Yoshito Itoh. (2022) Effect of concomitant use of G-CSF and myelosuppressive chemotherapy on bone marrow and peripheral granulocytes in a mouse model. Medical Oncology 39:8.
Crossref
Crossref
Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham & Ali McBride. (2022) Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. Future Oncology 18:19, pages 2381-2390.
Crossref
Crossref
Amanda J Gerberich, Mark R Attilio & Alison Svoboda. (2020) Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature. Journal of Oncology Pharmacy Practice 26:8, pages 1970-1976.
Crossref
Crossref
Takeshi Ishikawa, Tomoyo Yasuda, Tetsuya Okayama, Osamu Dohi, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Tomohisa Takagi, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Hideyuki Konishi, Yuji Naito, Satoshi Teramukai & Yoshito Itoh. (2019) Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Cancer Science 110:12, pages 3754-3760.
Crossref
Crossref
Heinz Ludwig, Pere Gascón, Carsten Bokemeyer, Matti Aapro, Mario Boccadoro, Kris Denhaerynck, Andriy Krendyukov, Karen MacDonald & Ivo Abraham. (2018) Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study. Supportive Care in Cancer 27:6, pages 2301-2312.
Crossref
Crossref
Betre Legesse, Amandeep Kaur, Doreswamy Kenchegowda, Bernadette Hritzo, William E. Culp & Maria Moroni. (2019) Neulasta Regimen for the Hematopoietic Acute Radiation Syndrome: Effects Beyond Neutrophil Recovery. International Journal of Radiation Oncology*Biology*Physics 103:4, pages 935-944.
Crossref
Crossref
R. Hultborn, P. Albertsson, S. Ottosson, E. Warnhammar, Å. Palm, S. Palm & K. Elmroth. (2019) Radiosensitivity: Gender and Order of Administration of G-CSF, An Experimental Study in Mice. Radiation Research 191:4, pages 335.
Crossref
Crossref
Matti Aapro, Ralph Boccia, Robert Leonard, Carlos Camps, Mario Campone, Sylvain Choquet, Marco Danova, John Glaspy, Iwona Hus, Hartmut Link, Thamer Sliwa, Hans Tesch & Vicente Valero. (2017) Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer 25:11, pages 3295-3304.
Crossref
Crossref
Arlene O. Siefker-Radtke, Matthew T. Campbell, Mark F. Munsell, Deborah R. Harris, Robert L. Carolla & Lance C. Pagliaro. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89, pages 83-89.
Crossref
Crossref
B. Linot, P. Augereau, R. Breheret, L. Laccourreye & O. Capitain. (2014) Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Supportive Care in Cancer 22:10, pages 2831-2837.
Crossref
Crossref
A. L. Romero-Weaver, X. S. Wan, E. S. Diffenderfer, L. Lin & A. R. Kennedy. (2013) Kinetics of Neutrophils in Mice Exposed to Radiation and/or Granulocyte Colony-Stimulating Factor Treatment. Radiation Research 180:2, pages 177-188.
Crossref
Crossref
D. Moro-Sibilot, A.-C. Toffart, G. Gereige & M. Coudurier. (2009) Les facteurs de croissance h?matopo??tique en canc?rologie thoracique. Revue des Maladies Respiratoires Actualit?s 1:4, pages 314-319.
Crossref
Crossref
Jenny M. Whitworth, Kellie S. Matthews, Kimberly A. Shipman, T. Michael Numnum, James E. Kendrick, Larry C. Kilgore & J. Michael StraughnJr.Jr.. (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecologic Oncology 112:3, pages 601-604.
Crossref
Crossref
Riccardo RicottaGiulio CereaIlaria SchiavettoMaria Rosaria MaugeriPaolo PedrazzoliSalvatore Siena. (2006) Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. Future Oncology 2:6, pages 667-676.
Crossref
Crossref
Jacob J. Lokich. (2006) Same Day Pegfilgrastim and CHOP Chemotherapy for Non-Hodgkin Lymphoma. American Journal of Clinical Oncology 29:4, pages 361-363.
Crossref
Crossref